Get started
TEVA PHARMACDRNTEVA PHARMACDRNTEVA PHARMACDRN

TEVA PHARMACDRN

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals Bonds

T1EV34 trade ideas

TEVA is recharging the battery waiting next earnings release ($TEVA) was accelerating the uptrend but since some days it has come back on its path inside a bullish flag. It is important to note that next week earnings will be released so high volatility should be expected. Masch is about to turn on bullish mode RSI is quite down and vortex is neutral. I might expect that some investors will get long before the earnings pushing the price up but it is just an hypothesis. So far we are still inside the range with lower and upper edges showed on the chart.
NYSE:TEVA
by TRADOMICS_
TEVA up trend is acceleratingAs showed in the picture trend is accelerating as a sign of streght for TEVA. After some consolidation pauses we have a situation where RSI in pointing up, MACD non really clear as we have had a lateral movement, volatility stop positive. Red trendline is showing the acceleration. TP around 27 first and 30 dollars after. Despite some up and down of nasdaq, Teva has held the hit continuing the lateral movement rather than going down, another sign of strenght at the moment.
NYSE:TEVALong
by TRADOMICS_
$TEVA - Berkshire breakout? Disclaimer, TEVA is in a very bad financial position, with dwindling cashflows and large debt. Buffet has always been the king of "value investing", hence why a position in Teva isn't surprising from him - it's most likely that he sees the company as severely undervalued and is entering into stages of repair. Buffet's new position in Teva was widely publicised this week: fortune.com markets.businessinsider.com finance.yahoo.com Just after Buffet disclosed the position, Teva announced the U.S. release of the QVAR Redihaler Inhalation Aerosol. www.streetinsider.com -new form of asthma inhalation treatment -breath actuated I don't think this is too important. I'd much rather to follow his other position into AAPL rather than TEVA
NYSE:TEVA
by UnknownUnicorn2421992
1
LONG $TEVAFrom looking at the chart patterns, I believe we will see a somewhat classic cup and handle pattern into the next few months. I am anticipating an upward breakout trend now that WB has increased his stake in the company and increases shareholder confidence . After consecutive bad earnings reports I believe this company will recover due to the modest estimates for next quarter. I also think analysts will increase their one year price targets once they have a positive earnings report. In my opinion a good buy and will be buying in next week after markets close Tuesday.
NYSE:TEVALong
by goodppldonttrade
Teva is now a buyAfter a couple of years where price has persistently followed the downtrend, last week Teva broke up such dynamic hreshold. Price has confirmed such trendline with a hammer 3 days ago at 17.04 dollars. Moreover we have the cross on the daily pattern between MA 50 and MA 200 turning to bullish set-up. Q1 earnings has been released beating expectations. SAR is positive and supertrend recently turned into bullish conformation as well. Trump is due to talk about drug prices this week but I don't deem Teva will be harshly impacted, because of the type of business. On a daily basis the hammer of three days ago confirmed by two green candles bear witness to a short term reversal. TP around 21.50/21.80
NYSE:TEVALong
by TRADOMICS_
TEVA Bullish bat pattern and demand zone before ERTEVA usually has HUGE move on its earning release day, which is 5/2. Here we got an bullish bat pattern but it's still way too far from the entry, while with regard to the potential huge move, it worth noticing beforehand and if it actually got crashed all the way there, it could be a high-risk high-reward trade! To start this trade ,there are 2 conditions to match 1. It gets slumped after ER 2. There are reversal signs between 11.50-12.00 Although it's still too early for this plan, but it doesn't hurt to make trading plans!! Let's see how it goes!
NYSE:TEVALong
by Trader_Joe_Lee
TEVA: Potential Value BuyPotential Buy opportunities are identified by the price levels at 16.75 / 14.75 (USD) Bullish Target (Long Term) 34.75 Berkshires average price is likely around 16.50~17 Research Sector: Pharma Publically Disclosed February 15 that Berkshire Hathaway bought shares but it is unclear exactly when they purchased 18,875,721 shares of the company when the price averaged around $15. The $357.7 million stake represents 1.86% of the company and merely 0.19% of the portfolio (4th Quarter 2017) In another 2017 development, Teva suspended its dividend. A cessation of shareholder payouts, dire results and heavy debt prompted the market to run from the stock. TEVA develops, manufactures and sells generic medicine in a range of forms including tablets, capsules, injectables, inhalants, liquids, oitments and creams. They also create specific specialty medicines that assist the Central Nervous System and Respiratory medicines focused on asthma and chronic obstructive pulmonary disease. One of their primary drugs is Copaxone.. used to treat multiple sclerosis however we are seeing more and more generic competition come into the marketplace Teva’s new Chief Executive Officer Kare Schultz laid out a vast cost-cutting plan in December, halting dividend payments and eliminating 25% of the global workforce. He has repeatedly stated that his biggest priority is to curb the company’s $31.4 billion debt pile.. Other Resources www.forbes.com Announcement of new asthma drug www.streetinsider.com Trading can contain substantial risk and is not suited for every investor. An investor could potentially lose all or more than their initial investment. "Risk capital" - is money that can be lost without jeopardizing ones financial security or life style. Only "risk capital" should be used for trading and only those with sufficient risk capital should consider trading. I am not a licensed financial advisor nor do I give out financial advice. You assumes full risk and responsibility for their trading activity. Past performance is not indicative of future results. Individual results will vary due to a variety of market and timing conditions.
NYSE:TEVALong
by ZacharyHogan